Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)
Status:
Completed
Trial end date:
2016-11-14
Target enrollment:
Participant gender:
Summary
The primary objective of this trial is to assess the safety of an uninterrupted dabigatran
etexilate periprocedural anticoagulant regimen compared to an uninterrupted warfarin regimen
in Non-Valvular Atrial Fibrillation (NVAF) patients undergoing Atrial Fibrillation (AF)
ablation in a PROBE (Prospective, randomized, open label, blinded end point) active
controlled study.
Secondary objectives are to assess additional safety endpoints and efficacy in this clinical
setting.
It is not intended to assess confirmatory hypothesis, this is an exploratory study.